Additional Information
Book Details
Abstract
This issue of Hospital Medicine Clinics, edited by Dr. Rachel Thompson, covers a broad spectrum of topics including: Cardiovascular Risk Assessment and Modification; Pulmonary Risk Assessment and Optimization, Diabetes and Hyperglycemia in the Surgical Setting; Management of Anticoagulants and VTE Prevention; Planning for Perioperative Pain Management; Medication Management for Patients on Chronic Steroids or Rheumatalogics; Anesthesia Considerations for the Hospitalist; Perioperative Assessment Of and Care for the Elderly and Frail; Quality and Value in Perioperative Medicine; Risk Assessment and Perioperative Care for Patients with Renal or Liver Disease; and Surgical Site Infections!
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover\r | 153 | ||
| Contributors | A1 | ||
| CONSULTING EDITOR | A1 | ||
| EDITOR | A1 | ||
| AUTHORS | A1 | ||
| Contents | A4 | ||
| Preface: High-Value, High-Quality Perioperative Care—A Collaborative Opportunity for Hospitalists\r | A4 | ||
| Value in the Perioperative Period\r | A4 | ||
| Perioperative Cardiac Risk Assessment and Management for Noncardiac Surgery\r | A4 | ||
| Pulmonary Risk Assessment and Optimization\r | A4 | ||
| Diabetes and Hyperglycemia in the Surgical Setting\r | A5 | ||
| Risk Assessment and Perioperative Care for Patients with Renal or Liver Disease\r | A5 | ||
| Perioperative Assessment of and Care for the Elderly and Frail\r | A5 | ||
| Venous Thromboembolism Prevention and Perioperative Management of Anticoagulants\r | A5 | ||
| Medication Management for Patients on Rheumatologic Agents or Chronic Steroids\r | A6 | ||
| Anesthesia Considerations for the Hospitalist\r | A6 | ||
| Planning for Perioperative Pain Management\r | A6 | ||
| Surgical Site Infections\r | A7 | ||
| HOSPITAL MEDICINE CLINICS\r | A8 | ||
| FORTHCOMING ISSUES | A8 | ||
| July 2016 | A8 | ||
| October 2016 | A8 | ||
| January 2017 | A8 | ||
| RECENT ISSUES | A8 | ||
| January 2016 | A8 | ||
| October 2015 | A8 | ||
| July 2015 | A8 | ||
| Preface:High-Value, High-Quality Perioperative Care—A Collaborative Opportunity for Hospitalists\r | A9 | ||
| Value in the Perioperative Period | 153 | ||
| Key points | 153 | ||
| VALUE IN THE POLICY CONTEXT | 154 | ||
| Value from the Payer’s Perspective | 154 | ||
| Value from Patients’ Perspective | 156 | ||
| PREOPERATIVE PERIOD | 157 | ||
| POSTOPERATIVE CARE | 157 | ||
| A Specific Example of Affecting Value | 157 | ||
| REFERENCES | 158 | ||
| Perioperative Cardiac Risk Assessment and Management for Noncardiac Surgery | 160 | ||
| INTRODUCTION | 161 | ||
| CLINICAL GUIDELINES | 161 | ||
| SURGICAL RISK AND TIMING | 161 | ||
| Coronary Artery Disease | 162 | ||
| Heart Failure | 162 | ||
| Valvular Heart Disease | 162 | ||
| Cardiomyopathy | 163 | ||
| Arrhythmias | 163 | ||
| A STEPWISE APPROACH SHOULD BE APPLIED | 165 | ||
| PERFORMANCE IMPROVEMENT | 167 | ||
| Coronary Artery Bypass Grafting and Percutaneous Coronary Interventions | 167 | ||
| β-Blockers | 168 | ||
| Statins | 170 | ||
| Other Medications: Clonidine and Aspirin | 171 | ||
| REFERENCES | 172 | ||
| Pulmonary Risk Assessment and Optimization | 176 | ||
| EPIDEMIOLOGY | 177 | ||
| PATIENT EVALUATION AND DIAGNOSIS | 177 | ||
| PATIENT MANAGEMENT | 182 | ||
| SUMMARY | 185 | ||
| REFERENCES | 186 | ||
| Diabetes and Hyperglycemia in the Surgical Setting | 189 | ||
| INTRODUCTION | 190 | ||
| All Persons Undergoing Surgery Are at Risk | 190 | ||
| Persons with Known Diabetes and Prediabetes | 191 | ||
| Persons with Undiagnosed Diabetes and Prediabetes | 191 | ||
| PREOPERATIVE EVALUATION | 193 | ||
| Hemoglobin A1c | 195 | ||
| Other Testing | 196 | ||
| INTRAOPERATIVE | 197 | ||
| POSTOPERATIVE | 198 | ||
| REFERENCES | 200 | ||
| Risk Assessment and Perioperative Care for Patients with Renal or Liver Disease | 205 | ||
| PERIOPERATIVE CARE FOR PATIENTS WITH RENAL DISEASE | 207 | ||
| Introduction | 207 | ||
| Conclusion | 211 | ||
| PERIOPERATIVE CARE FOR PATIENTS WITH LIVER DISEASE | 212 | ||
| Risk Factors for Liver Disease | 212 | ||
| Preoperatively | 219 | ||
| Postoperatively | 219 | ||
| REFERENCES | 220 | ||
| Perioperative Assessment of and Care for the Elderly and Frail | 224 | ||
| BACKGROUND AND SIGNIFICANCE | 225 | ||
| The Aging of the Population and Surgery | 225 | ||
| Current Challenges in Perioperative Management of Elderly and Frail Patients | 225 | ||
| Perioperative Assessment of the Elderly | 225 | ||
| Calculating the surgical risk for elderly patients | 226 | ||
| Cardiac and pulmonary risk assessment in the elderly | 226 | ||
| Elderly-specific assessment | 227 | ||
| Cognitive function | 227 | ||
| Decision-making capacity | 227 | ||
| Functional status | 228 | ||
| Self-reported Measures | 229 | ||
| Performance-based Assessments | 230 | ||
| Nutritional status | 230 | ||
| Frailty and its impact on postoperative outcomes | 231 | ||
| THE ROLE OF MEDICAL PERIOPERATIVE CLINICS, AND GERIATRIC AND MEDICAL COMANAGEMENT PROGRAMS | 235 | ||
| SUMMARY AND FUTURE DIRECTIONS | 237 | ||
| ACKNOWLEDGMENTS | 239 | ||
| REFERENCES | 239 | ||
| Venous Thromboembolism Prevention and Perioperative Management of Anticoagulants | 242 | ||
| DEFINITIONS | 243 | ||
| RISK ASSESSMENT | 244 | ||
| PHARMACOLOGIC OPTIONS FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS AND TREATMENT | 246 | ||
| NONPHARMACOLOGIC OPTIONS FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS | 252 | ||
| VENOUS THROMBOEMBOLISM PROPHYLAXIS IN SURGICAL PATIENTS | 252 | ||
| TIMING OF CESSATION OF ANTICOAGULATION, RESUMPTION, AND DURATION OF TREATMENT | 254 | ||
| INTERRUPTIONS IN VENOUS THROMBOEMBOLISM TREATMENT AND BRIDGING STRATEGIES | 260 | ||
| REVERSAL | 263 | ||
| REFERENCES | 263 | ||
| Medication Management for Patients on Rheumatologic Agents or Chronic Steroids | 268 | ||
| PERIOPERATIVE MANAGEMENT OF RHEUMATOLOGIC AGENTS | 269 | ||
| PERIOPERATIVE MANAGEMENT OF CORTICOSTEROIDS | 274 | ||
| PATIENT SELECTION TO RECEIVE PERIOPERATIVE STRESS-DOSE STEROIDS | 277 | ||
| WEIGHING THE RISKS AND BENEFITS | 278 | ||
| REFERENCES | 278 | ||
| Anesthesia Considerations for the Hospitalist | 281 | ||
| ANESTHESIA PRIMER | 282 | ||
| Anesthetic Drugs | 282 | ||
| Analgesics | 282 | ||
| Anxiolytics/Sedatives | 283 | ||
| Neuromuscular Blockers | 283 | ||
| Preprocedural Assessment | 284 | ||
| Induction | 285 | ||
| Maintenance of Anesthesia | 286 | ||
| Emergence | 286 | ||
| Monitored Anesthesia Care | 287 | ||
| General Anesthesia | 287 | ||
| ACUTE SEQUELAE OF ANESTHESIA | 287 | ||
| THE HOSPITALIST AND QUALITY IMPROVEMENT | 294 | ||
| REFERENCES | 298 | ||
| Planning for Perioperative Pain Management | 303 | ||
| PREOPERATIVE CONSIDERATIONS | 304 | ||
| OPIOIDS | 304 | ||
| NONOPIOID SYSTEMIC PAIN MEDICATIONS | 306 | ||
| REGIONAL PAIN CONTROL | 308 | ||
| SPECIAL POPULATIONS | 310 | ||
| PROCESS IMPROVEMENTS | 315 | ||
| GUIDELINES | 315 | ||
| REFERENCES | 315 | ||
| Surgical Site Infections | 319 | ||
| DEFINITIONS | 320 | ||
| BACKGROUND/EPIDEMIOLOGY | 320 | ||
| PATHOGENESIS | 321 | ||
| PREVENTION | 322 | ||
| DIAGNOSIS AND MANAGEMENT | 327 | ||
| PROCESS IMPROVEMENT | 329 | ||
| REFERENCES | 330 |